Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Within R&D, Novo Nordisk completed the REDEFINE 2 trial, where CagriSema demonstrated superior weight loss of 15.7% in adults with obesity or overweight and type 2 diabetes. Novo Nordisk still ...

Notably, its experimental drug CagriSema has fallen short of market expectations, leading to a decline in share price despite the treatment meeting primary endpoints in studies. Meanwhile, current GLP ...

Another challenge for Novo Nordisk has been disappointing trial results for CagriSema, its next-generation obesity treatment. Despite the setbacks, Jørgensen had remained publicly confident in ...

All figures are at CER. Novo Nordisk also highlighted the completion of its REDEFINE 2 trial for CagriSema, its next-generation obesity drug. The treatment delivered a 15.7% weight reduction.

However, the company has struggled to shake negative sentiment following a series of disappointing trial results for its next-generation obesity drug candidate CagriSema. Novo Nordisk confirmed ...